Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Feb 16;25(2):778.
doi: 10.1093/europace/euac208.

Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke: comment-Authors' reply

W F McIntyre  1 , J S Healey  1
Affiliations
Comment

Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke: comment-Authors' reply

W F McIntyre et al. Europace. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have no conflicts of interest to declare.

Comment in

Comment on

References

    1. McIntyre WF, Wang J, Benz AP, Johnson L, Connolly SJ, Van Gelder ICet al. . Estimated incidence of previously undetected atrial fibrillation on a 14-day continuous electrocardiographic monitor and associated risk of stroke. Europace 2022;24:1058–64. - PubMed
    1. Van Gelder IC, Healey JS, Crijns H, Wang J, Hohnloser SH, Gold MRet al. . Duration of device-detected subclinical atrial fibrillation and occurrence of stroke in ASSERT. Eur Heart J 2017;38:1339–44. - PubMed
    1. Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SDet al. . Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med 2018;378:2191–201. - PubMed
    1. Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AEet al. . Recurrent stroke with rivaroxaban compared with aspirin according to predictors of atrial fibrillation: secondary analysis of the NAVIGATE ESUS randomized clinical trial. JAMA Neurol 2019;76:764–73. - PMC - PubMed
    1. Kaufman ES, Israel CW, Nair GM, Armaganijan L, Divakaramenon S, Mairesse GHet al. . Positive predictive value of device-detected atrial high-rate episodes at different rates and durations: an analysis from ASSERT. Heart Rhythm 2012;9:1241–6. - PubMed